SG11201901020RA - Anti-siglec-7 antibodies for the treatment of cancer - Google Patents
Anti-siglec-7 antibodies for the treatment of cancerInfo
- Publication number
- SG11201901020RA SG11201901020RA SG11201901020RA SG11201901020RA SG11201901020RA SG 11201901020R A SG11201901020R A SG 11201901020RA SG 11201901020R A SG11201901020R A SG 11201901020RA SG 11201901020R A SG11201901020R A SG 11201901020RA SG 11201901020R A SG11201901020R A SG 11201901020RA
- Authority
- SG
- Singapore
- Prior art keywords
- suite
- california
- international
- shoreway
- san
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 231100000673 dose–response relationship Toxicity 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371680P | 2016-08-05 | 2016-08-05 | |
| PCT/US2017/045641 WO2018027203A1 (en) | 2016-08-05 | 2017-08-04 | Anti-siglec-7 antibodies for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901020RA true SG11201901020RA (en) | 2019-03-28 |
Family
ID=61073084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901020RA SG11201901020RA (en) | 2016-08-05 | 2017-08-04 | Anti-siglec-7 antibodies for the treatment of cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11773162B2 (es) |
| EP (1) | EP3494142A4 (es) |
| JP (1) | JP7137563B2 (es) |
| KR (1) | KR20190035863A (es) |
| CN (1) | CN109790223A (es) |
| AU (1) | AU2017307616A1 (es) |
| BR (1) | BR112019002331A2 (es) |
| CA (1) | CA3032437A1 (es) |
| EA (1) | EA201990296A1 (es) |
| IL (1) | IL264674B2 (es) |
| MX (1) | MX2019001471A (es) |
| SG (1) | SG11201901020RA (es) |
| WO (1) | WO2018027203A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| EA201990296A1 (ru) | 2016-08-05 | 2019-08-30 | Аллакос, Инк. | Антитела против siglec-7 для лечения рака |
| KR102376863B1 (ko) | 2017-05-12 | 2022-03-21 | 하푼 테라퓨틱스, 인크. | 메소텔린 결합 단백질 |
| US11447545B2 (en) | 2017-07-10 | 2022-09-20 | Innate Pharma | Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer |
| CN111465612A (zh) | 2017-10-13 | 2020-07-28 | 哈普恩治疗公司 | B细胞成熟抗原结合蛋白 |
| JP7342005B2 (ja) * | 2018-01-11 | 2023-09-11 | アラコス，インコーポレイティド | エフェクター機能が減少した抗ｓｉｇｌｅｃ－７抗体 |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| EP4370552A1 (en) | 2021-07-13 | 2024-05-22 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
| PL220113B1 (pl) | 1999-01-15 | 2015-08-31 | Genentech Inc | Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc |
| EP2270150B2 (en) | 1999-04-09 | 2019-08-07 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| WO2003035835A2 (en) | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Glycoprotein compositions |
| WO2007120815A2 (en) * | 2006-04-12 | 2007-10-25 | The Regents Of The University Of California | Methods for treating lymphocyte-associated disorders by modulation of siglec activity |
| JP5938816B2 (ja) * | 2007-07-04 | 2016-06-22 | 中外製薬株式会社 | 抗Ｍｕｃ１７抗体 |
| EP2817338B1 (en) | 2012-02-24 | 2017-07-26 | AbbVie Stemcentrx LLC | Dll3 modulators and methods of use |
| ES2791183T3 (es) * | 2012-12-21 | 2020-11-03 | Aveo Pharmaceuticals Inc | Anticuerpos anti-GDF15 |
| EP2999717B1 (en) * | 2013-05-21 | 2018-08-08 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Treatment of mast cell related pathologies |
| MY196283A (en) | 2014-08-07 | 2023-03-24 | Daiichi Sankyo Co Ltd | Anti-Orai1 Antibody |
| DK3191517T3 (da) * | 2014-09-10 | 2021-01-25 | Innate Pharma | Krydsreaktive siglec-antistoffer |
| KR20180054639A (ko) * | 2015-08-28 | 2018-05-24 | 알렉터 엘엘씨 | 항-siglec-7 항체 및 이의 사용 방법 |
| EP3402516A4 (en) * | 2016-01-12 | 2020-01-08 | Palleon Pharmaceuticals Inc. | USE OF ANTIBODIES DIRECTED AGAINST SIGLEC-7 OR SIGLEC-9 IN THE TREATMENT OF CANCER |
| EP3426688A1 (en) * | 2016-03-08 | 2019-01-16 | Innate Pharma | Siglec neutralizing antibodies |
| EA201990296A1 (ru) | 2016-08-05 | 2019-08-30 | Аллакос, Инк. | Антитела против siglec-7 для лечения рака |
-
2017
- 2017-08-04 EA EA201990296A patent/EA201990296A1/ru unknown
- 2017-08-04 WO PCT/US2017/045641 patent/WO2018027203A1/en unknown
- 2017-08-04 US US16/323,442 patent/US11773162B2/en active Active
- 2017-08-04 IL IL264674A patent/IL264674B2/en unknown
- 2017-08-04 JP JP2019527783A patent/JP7137563B2/ja active Active
- 2017-08-04 MX MX2019001471A patent/MX2019001471A/es unknown
- 2017-08-04 CA CA3032437A patent/CA3032437A1/en active Pending
- 2017-08-04 CN CN201780060307.2A patent/CN109790223A/zh active Pending
- 2017-08-04 KR KR1020197006520A patent/KR20190035863A/ko not_active Application Discontinuation
- 2017-08-04 BR BR112019002331A patent/BR112019002331A2/pt unknown
- 2017-08-04 AU AU2017307616A patent/AU2017307616A1/en active Pending
- 2017-08-04 EP EP17837808.9A patent/EP3494142A4/en active Pending
- 2017-08-04 SG SG11201901020RA patent/SG11201901020RA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11773162B2 (en) | 2023-10-03 |
| EP3494142A1 (en) | 2019-06-12 |
| IL264674B2 (en) | 2023-09-01 |
| EA201990296A1 (ru) | 2019-08-30 |
| WO2018027203A1 (en) | 2018-02-08 |
| JP7137563B2 (ja) | 2022-09-14 |
| BR112019002331A2 (pt) | 2019-06-18 |
| US20190194323A1 (en) | 2019-06-27 |
| KR20190035863A (ko) | 2019-04-03 |
| EP3494142A4 (en) | 2020-04-01 |
| CN109790223A (zh) | 2019-05-21 |
| CA3032437A1 (en) | 2018-02-08 |
| IL264674B1 (en) | 2023-05-01 |
| JP2019526622A (ja) | 2019-09-19 |
| IL264674A (es) | 2019-03-31 |
| AU2017307616A1 (en) | 2019-02-28 |
| MX2019001471A (es) | 2019-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201807401RA (en) | Therapeutic membrane vesicles | |
| SG11201810509PA (en) | Anti-pd-l1 antibodies | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201903835WA (en) | Antibodies directed against programmed death- 1 (pd-1) | |
| SG11201807785VA (en) | Neuroactive steroids, compositions, and uses thereof | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201908051RA (en) | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201804856VA (en) | C-terminal lysine conjugated immunoglobulins |